Myeloma, Multiple Clinical Trials

13 recruiting

Frequently Asked Questions

Common questions about Myeloma, Multiple clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Phase 2

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

Myeloma, Multiple
M.D. Anderson Cancer Center94 enrolled1 locationNCT05091372
Recruiting
Not Applicable

Feasibility of a Multi-omics Platform for Hematological Malignancies

Acute LeukemiaChronic LeukemiaLymphoproliferative Disorders+3 more
Azienda Ospedaliero-Universitaria di Parma1,040 enrolled1 locationNCT07445438
Recruiting
Phase 1

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Multiple MyelomaMyelomaMyeloma, Multiple
K36 Therapeutics, Inc.125 enrolled22 locationsNCT05651932
Recruiting
Phase 2

A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

MyelomaMyeloma, Multiple
AHS Cancer Control Alberta100 enrolled2 locationsNCT04268199
Recruiting
Not Applicable

e-Motion : Promoting Emotion Regulation in Chronic Cancer

Myeloma, MultipleMetastatic Cancers
Université Libre de Bruxelles30 enrolled2 locationsNCT07236021
Recruiting
Phase 2

Limited-duration Teclistamab

Myeloma, Multiple
Abramson Cancer Center at Penn Medicine75 enrolled5 locationsNCT05932680
Recruiting

High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)

Multiple MyelomaMyelodysplastic SyndromeLymphoma+12 more
Yigeng Cao,MD,PhD1,000 enrolled1 locationNCT07205523
Recruiting
Not Applicable

Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients

Lymphoma, Non-HodgkinMyeloma, Multiple
Assistance Publique - Hôpitaux de Paris30 enrolled1 locationNCT06133426
Recruiting
Phase 1

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

NeoplasmLymphoproliferative DisordersNeoplasms by Histologic Type+11 more
Kelonia Therapeutics, Inc.40 enrolled3 locationsNCT07075185
Recruiting
Phase 1Phase 2

The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors

AML (Acute Myelogenous Leukemia)B-ALLMyeloma, Multiple+3 more
Tianjin Medical University General Hospital90 enrolled1 locationNCT06911710
Recruiting

The Norwegian Immunotherapy in Multiple Myeloma Study

Plasma Cell LeukemiaMyeloma, MultipleAL Amyloidosis
St. Olavs Hospital400 enrolled23 locationsNCT06855121
Recruiting

Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma

Myeloma, Multiple
Uppsala University100 enrolled1 locationNCT06245629
Recruiting

Fluciclovine PET/CT in Multiple Myeloma Patients

PET/CTMyeloma, Multiple
Oslo University Hospital10 enrolled1 locationNCT03966443